The impact of cancer on diabetes outcomes

Abstract

Background Survival from many cancer types is steadily increasing, and as a result, a growing number of cancer patients will live with other chronic diseases, of which diabetes is one of the most prevalent. This study aims to describe the impact of cancer on health outcomes in patients with type 2 diabetes and to compare the effectiveness of a multifactorial intervention in diabetes patients with and without cancer. Methods The randomized controlled trial Diabetes Care in General Practice (DCGP) included 1381 patients newly diagnosed with type 2 diabetes. Patients were randomized to either six years of structured personal diabetes care or routine care. In a post hoc analysis, we followed patients for 19 years in Danish national registries for the occurrence of diabetes-related outcomes. We used Cox regression models to estimate hazard ratios for outcomes. Results At diagnosis 48 patients had cancer, and 243 patients were diagnosed with cancer during follow up. Patients with diabetes and cancer had excess all-cause mortality (HR 3.33; 95%CI 2.72–4.06), as well as an increased incidence of myocardial infarction (HR 1.76; 95%CI 1.29–2.39) and any diabetes-related outcome (HR 1.36; 95%CI 1.07–1.71). The intervention reduced the risk of both these endpoints in patients without cancer. Furthermore, there was no statistically significant difference in the effectiveness of the intervention among patients with and without cancer. Conclusions Diabetes patients with cancer had an increased risk of myocardial infarction and any diabetes-related outcome. The observed positive effect of structured personal diabetes care on clinical outcomes did not differ between patients with and without cancer. Attention to and prevention of diabetes complications in patients with both type 2 diabetes and cancer is warranted. Trial registration ClinicalTrials.gov NCT01074762 (February 24, 2010). Electronic supplementary material The online version of this article (10.1186/s12902-019-0377-0) contains supplementary material, which is available to authorized users.

New onset of type 2 diabetes after colorectal cancer diagnosis: Results from three prospective US cohort studies, systematic review, and meta-analysis

“… 39 We suspect the diagnosis and treatment of cancer may distract patients and health care providers from the appropriate prevention and management of other chronic diseases including T2D, or perhaps there are social determinants of health in terms of access to care at play. 40 Important to highlight is that many CRC survivors and their primary care providers are often unaware of this phenomenon, ultimately manifesting in negative impact of long-term health outcomes. 22 , 31 Improving awareness of this clinical scenario may help improve cancer patients’ treatment safety and treatment efficacy.…”

Cardiometabolic Comorbidities in Cancer Survivors

“…In cancer patients, several factors are likely to contribute to the association of diabetes with increased cardiovascular morbidity 120 and all-cause mortality. 121 , 122 First, diabetes may inherently limit access to life-saving cancer therapies; for instance, registry data from 194 Hodgkin’s lymphoma patients found that those with diabetes received less chemotherapy.…”

Influence of Diabetes Mellitus on Levels of Sex Hormones and Their Receptors in Tumor Tissues in Female Rats With Guerin Carcinoma and in Female Balb/C Nude Mice With Lewis Carcinoma

“…Повышение эффективности лечения онкологических больных в последнее десятилетие и связанное с этим улучшение их выживаемости способствуют росту доли пациентов с несколькими сопутствующими хроническими заболеваниями, среди которых одним из наиболее распространенных является сахарный диабет (СД). Однако состояние мультиморбидности связано с худшим клиническим исходом и повышенной смертностью [1,2]. СД увеличивает риск развития многих сопутствующих патологий, в том числе риск развития злокачественных опухолей: установлено увеличение заболеваемости раком у больных СД на 15-30% [3,4].…”